{"name": "ImmunoGen",
 "permalink": "immunogen",
 "crunchbase_url": "http://www.crunchbase.com/company/immunogen",
 "homepage_url": "http://www.immunogen.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 1981,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "781-895-0600",
 "description": "",
 "created_at": "Sat Nov 21 03:45:34 UTC 2009",
 "updated_at": "Wed Dec 21 03:31:06 UTC 2011",
 "overview": "\u003Cp\u003EImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin\u00e2\u20ac\u2122s lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company\u00e2\u20ac\u2122s products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       15],
      "assets/images/resized/0006/7077/67077v1-max-150x150.png"],
     [[250,
       25],
      "assets/images/resized/0006/7077/67077v1-max-250x250.png"],
     [[285,
       29],
      "assets/images/resized/0006/7077/67077v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Chairman",
    "person":
     {"first_name": "Stephen",
      "last_name": "C. McCluski",
      "permalink": "stephen-c-mccluski",
      "image": null}},
   {"is_past": false,
    "title": "President \u0026 CEO",
    "person":
     {"first_name": "Daniel",
      "last_name": "M. Junius",
      "permalink": "daniel-m-junius",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Gregory",
      "last_name": "D. Perry",
      "permalink": "gregory-d-perry",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$26M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://www.masshightech.com/stories/2011/06/13/daily29-Bayer-IND-submission-earns-ImmunoGen-2M-payment.html",
    "source_description": "Bayer IND submission earns ImmunoGen $2M payment",
    "raised_amount": 2000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 6,
    "funded_day": 15,
    "investments":
     []},
   {"round_code": "unattributed",
    "source_url": "http://www.masshightech.com/stories/2011/10/17/daily44-ImmunoGen-lands-3M-Sanofi-payment.html",
    "source_description": "ImmunoGen lands $3M Sanofi payment",
    "raised_amount": 3000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 10,
    "funded_day": 20,
    "investments":
     []},
   {"round_code": "angel",
    "source_url": "http://www.masshightech.com/stories/2011/11/14/daily7-ImmunoGen-scores-another-1M-pay-in-second-Amgen-deal.html",
    "source_description": "ImmunoGen scores another $1M pay in second Amgen deal",
    "raised_amount": 1000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 11,
    "funded_day": 14,
    "investments":
     []},
   {"round_code": "unattributed",
    "source_url": "http://www.fiercebiotech.com/story/immunogen-banks-20m-new-antibody-cancer-drug-pact-lilly/2011-12-20?utm_medium=rss\u0026utm_source=rss",
    "source_description": "ImmunoGen banks $20M on new antibody cancer drug pact with Lilly",
    "raised_amount": 20000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 12,
    "funded_day": 20,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "830 Winter Street",
    "address2": "",
    "zip_code": "02451-1477",
    "city": "Waltham",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "ImmunoGen begins clinical tests of cancer treatment",
    "stoned_year": 2010,
    "stoned_month": 9,
    "stoned_day": 21,
    "source_url": "http://www.masshightech.com/stories/2010/09/20/daily25-ImmunoGen-begins-clinical-tests-of-cancer-treatment.html",
    "source_text": null,
    "source_description": "ImmunoGen begins clinical tests of cancer treatment",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "ImmunoGen",
      "permalink": "immunogen"}},
   {"description": "ImmunoGen Inc. has agreed to work with Novartis on targeted anticancer therapeutics",
    "stoned_year": 2010,
    "stoned_month": 10,
    "stoned_day": 11,
    "source_url": "http://www.masshightech.com/stories/2010/10/11/daily59-ImmunoGen-licenses-TAP-tech-to-Novartis-in-245M--deal.html",
    "source_text": null,
    "source_description": "ImmunoGen licenses TAP tech to Novartis in $245M+ deal",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "ImmunoGen",
      "permalink": "immunogen"}},
   {"description": "Reports positive clinical data in relation to trastuzumb-DM1, its treatment of breast cancer",
    "stoned_year": 2010,
    "stoned_month": 10,
    "stoned_day": 11,
    "source_url": "http://www.masshightech.com/stories/2010/10/11/daily68-ImmunoGen-breast-cancer-treatment-shows-promising-results.html",
    "source_text": null,
    "source_description": "ImmunoGen breast cancer treatment shows promising results",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "ImmunoGen",
      "permalink": "immunogen"}},
   {"description": "has begun a clinical trial of its small-cell lung cancer treatment, IMGN901",
    "stoned_year": 2010,
    "stoned_month": 11,
    "stoned_day": 30,
    "source_url": "http://www.masshightech.com/stories/2010/11/29/daily26-ImmunoGen-testing-lung-cancer-treatment.html",
    "source_text": null,
    "source_description": "ImmunoGen testing lung cancer treatment",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "ImmunoGen",
      "permalink": "immunogen"}},
   {"description": "Theresa Wingrove has been named vice president of regulatory affairs\r\n",
    "stoned_year": 2011,
    "stoned_month": 1,
    "stoned_day": 18,
    "source_url": "http://www.masshightech.com/stories/2011/01/17/daily18-Wingrove-to-head-regulatory-affairs-at-ImmunoGen.html",
    "source_text": null,
    "source_description": "Wingrove to head regulatory affairs at ImmunoGen",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "ImmunoGen",
      "permalink": "immunogen"}},
   {"description": "ImmunoGen wins $1M milestone payment from Amgen deal",
    "stoned_year": 2011,
    "stoned_month": 11,
    "stoned_day": 3,
    "source_url": "http://www.masshightech.com/stories/2011/10/31/daily39-ImmunoGen-wins-1M-milestone-payment-from-Amgen-deal.html",
    "source_text": "",
    "source_description": "ImmunoGen wins $1M milestone payment from Amgen deal",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "ImmunoGen",
      "permalink": "immunogen"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}